Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Clinical trial NCT06858410 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06858410
- Sponsor
- Guangdong Association of Clinical Trials
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2030-03-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.